Summit’s WCLC data reinforce ivonescimab survival benefit ahead of FDA decision

Summit is a clinical-stage oncology company built around ivonescimab, with the HARMONi study serving as the basis for its U.S. regulatory application and a November 14, 2026 FDA action date. The company is now trying to convert a promising global trial package into its first potential U.S. approval.

The core HARMONi result held up with longer follow-up. The June 2026 global analysis improved the overall-survival hazard ratio to 0.76 from 0.79 at the primary analysis, with the confidence interval now below 1.0; the western subgroup produced the same 0.76 hazard ratio after median follow-up extended to 23.2 months. 〔0〕

The meaningful change is validation, not a new efficacy surprise. Summit had already disclosed the direction of the HARMONi update on July 22, including the western subgroup result, so this filing mainly confirms durability and geographic consistency rather than resetting the clinical story. 〔1〕 That makes the result partly known, but the longer follow-up removes some of the earlier uncertainty caused by limited western observation time.

The data strengthen the regulatory case without eliminating the remaining caveat. HARMONi’s primary OS analysis did not reach statistical significance, while the updated analysis is nominally significant; that distinction matters because the FDA application is still being judged against the full evidence package, not just this later data cut. The western confidence interval also still crosses 1.0, reflecting the smaller subgroup, even though its point estimate matches the global result.

HARMONi-2 adds breadth, but it is supportive rather than equivalent evidence. The China-only study showed a statistically significant survival advantage over pembrolizumab, but the release states that Akeso exclusively generated, managed, and analyzed those data. 〔2〕 That result supports ivonescimab’s broader clinical thesis, but it does not carry the same direct weight for Summit’s U.S. filing as the global HARMONi study.

Safety remains supportive, with one visible trade-off. Summit reports no new safety signals in either update, and HARMONi-2 treatment-related adverse events leading to discontinuation or death were numerically lower with ivonescimab; however, serious treatment-related adverse events were higher at 29.9% versus 21.6%. 〔3〕

Bottom line: This is a modestly positive confirmation of Summit’s central regulatory story: HARMONi’s survival benefit persisted and looked consistent in western patients after longer follow-up. It matters mainly because it reduces durability and regional-consistency concerns ahead of the November 14 FDA decision, rather than because it delivers a wholly new result.